Mesd C-terminal region peptide inhibits prostate cancer PC-3 and breast cancer HS578T cell proliferation.

<p>(A) Cancer cells in 6-well plates were treated with mouse Mesd (mMesd, 2 µM), human Mesd peptide hMesd (160–197) (4 µM) or control peptide (4 µM) in RPMI-1640 medium containing 2% FBS for PC-3 cells or DMEM medium containing 2% FBS for HS578T for 10 days. The media were changed every other day, and cells were harvested and counted using the trypan blue exclusion assay. Values are averages of three determinations with the standard deviations indicated by error bars. ** <i>P</i><0.01 compared to the cells treated with PBS or control peptide. (B) Cancer cells in T-25 flasks were treated with human Mesd peptide hMesd (160–197) (2 µM) or control peptide (2 µM) in the culture medium containing 2% FBS for 7 days. The media were changed every other day. The cells were then harvested and seeded into 96-well tissue culture plates at a density of 5000 cells/well with hMesd (160–197) (2 µM) or control peptide (2 µM) in the culture medium containing 10% FBS for 2 days. Cell proliferation was measured by BrdU proliferation ELISA. All the values are the average of six determinations with the s.d. indicated by error bars. <i>**P<0.01</i> compared to cells treated with control peptide.